Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis

Thomas C Kwee, Robert M Kwee, Thomas C Kwee, Robert M Kwee

Abstract

The aim of this study was to systematically review and meta-analyze published data on the diagnostic performance of combined 18F-fluoro-2-deoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) in the detection of primary tumors in patients with cancer of unknown primary (CUP). A systematic search for relevant studies was performed of the PubMed/MEDLINE and Embase databases. Methodological quality of the included studies was assessed. Reported detection rates, sensitivities and specificities were meta-analyzed. Subgroup analyses were performed if results of individual studies were heterogeneous. The 11 included studies, comprising a total sample size of 433 patients with CUP, had moderate methodological quality. Overall primary tumor detection rate, pooled sensitivity and specificity of FDG-PET/CT were 37%, 84% (95% CI 78-88%) and 84% (95% CI 78-89%), respectively. Sensitivity was heterogeneous across studies (P = 0.0001), whereas specificity was homogeneous across studies (P = 0.2114). Completeness of diagnostic workup before FDG-PET/CT, location of metastases of unknown primary, administration of CT contrast agents, type of FDG-PET/CT images evaluated and way of FDG-PET/CT review did not significantly influence diagnostic performance. In conclusion, FDG-PET/CT can be a useful method for unknown primary tumor detection. Future studies are required to prove the assumed advantage of FDG-PET/CT over FDG-PET alone and to further explore causes of heterogeneity.

Figures

Fig. 1
Fig. 1
Locations of primary tumours detected by FDG-PET/CT
Fig. 2
Fig. 2
Locations of false-positive FDG-PET/CT findings
Fig. 3
Fig. 3
Locations of false-negative FDG-PET/CT findings

References

    1. Pavlidis N. Forty years experience of treating cancer of unknown primary. Acta Oncol. 2007;46:592–601. doi: 10.1080/02841860701243095.
    1. Pavlidis N, Briasoulis E, Hainsworth J, Greco FA. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer. 2003;39:1990–2005. doi: 10.1016/S0959-8049(03)00547-1.
    1. Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology. 2004;231:305–332. doi: 10.1148/radiol.2312021185.
    1. Sève P, Billotey C, Broussolle C, Dumontet C, Mackey JR. The role of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site. Cancer. 2007;109:292–299. doi: 10.1002/cncr.22410.
    1. Rusthoven KE, Koshy M, Paulino AC. The role of fluorodeoxyglucose positron emission tomography in cervical lymph node metastases from an unknown primary tumor. Cancer. 2004;101:2641–2649. doi: 10.1002/cncr.20687.
    1. Delgado-Bolton RC, Fernández-Pérez C, González-Maté A, Carreras JL. Meta-analysis of the performance of 18F-FDG PET in primary tumor detection in unknown primary tumors. J Nucl Med. 2003;44:1301–1314.
    1. Blodgett TM, Meltzer CC, Townsend DW. PET/CT: form and function. Radiology. 2007;242:360–385. doi: 10.1148/radiol.2422051113.
    1. Von Schulthess GK, Steinert HC, Hany TF. Integrated PET/CT: current applications and future directions. Radiology. 2006;238:405–422. doi: 10.1148/radiol.2382041977.
    1. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 2003;3:25. doi: 10.1186/1471-2288-3-25.
    1. Whiting PF, Weswood ME, Rutjes AW, Reitsma JB, Bossuyt PN, Kleijnen J. Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies. BMC Med Res Methodol. 2006;6:9. doi: 10.1186/1471-2288-6-9.
    1. Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol. 2006;6:31. doi: 10.1186/1471-2288-6-31.
    1. Fencl P, Belohlavek O, Skopalova M, Jaruskova M, Kantorova I, Simonova K. Prognostic and diagnostic accuracy of [18F]FDG-PET/CT in 190 patients with carcinoma of unknown primary. Eur J Nucl Med Mol Imaging. 2007;34:1783–1792. doi: 10.1007/s00259-007-0456-8.
    1. Nassenstein K, Veit-Haibach P, Stergar H, et al. Cervical lymph node metastases of unknown origin: primary tumor detection with whole-body positron emission tomography/computed tomography. Acta Radiol. 2007;23:1–8.
    1. Fleming AJ, Jr, Smith SP, Jr, Paul CM, et al. Impact of [18F]-2-fluorodeoxyglucose-positron emission tomography/computed tomography on previously untreated head and neck cancer patients. Laryngoscope. 2007;117:1173–1179. doi: 10.1097/MLG.0b013e31805d017b.
    1. Bruna C, Journo A, Netter F, et al. On the interest of PET with 18F-FDG in the management of cancer of unknown primary (CUP) Med Nucl. 2007;31:242–249.
    1. Wartski M, Le Stanc E, Gontier E, et al. In search of an unknown primary tumor presenting with cervical metastases: performance of hybrid FDG-PET-CT. Nucl Med Commun. 2007;28:365–371. doi: 10.1097/MNM.0b013e3280708edf.
    1. Paul SA, Stoeckli SJ, von Schulthess GK, Goerres GW. FDG PET and PET/CT for the detection of the primary tumor in patients with cervical non-squamous cell carcinoma metastasis of an unknown primary. Eur Arch Otorhinolaryngol. 2007;264:189–195. doi: 10.1007/s00405-006-0177-9.
    1. Ambrosini V, Nanni C, Rubello D, et al. 18F-FDG PET/CT in the assessment of carcinoma of unknown primary origin. Radiol Med (Torino) 2006;111:1146–1155. doi: 10.1007/s11547-006-0112-6.
    1. Schneider K, Hrasky A, Aschoff P, Bihl H, Hagen R. Significance of PET and integrated PET/CT in the diagnostics of occult primary tumors. Laryngorhinootologie. 2006;85:819–823. doi: 10.1055/s-2006-925297.
    1. Fakhry N, Barberet M, Lussato D, et al. Role of [18F]-FDG PET-CT in the management of the head and neck cancers. Bull Cancer. 2006;93:1017–1025.
    1. Schneider K, Aschoff P, Bihl H, Hagen R. The integrated PET/CT: technological advance in diagnostics of head and neck recurrencies and CUP? Laryngorhinootologie. 2006;85:179–183. doi: 10.1055/s-2005-870509.
    1. Pelosi E, Pennone M, Deandreis D, Douroukas A, Mancini M, Bisi G. Role of whole body positron emission tomography/computed tomography scan with 18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site. Q J Nucl Med Mol Imaging. 2006;50:15–22.
    1. Maldonado A, Gonzalez Alenda J. The anatomicometabolic PET-CT in carcinoma of unknown primary site. Oncologia (Spain) 2006;29:93–94. doi: 10.1159/000091149.
    1. Fakhry N, Jacob T, Paris J, et al. Contribution of 18-F-FDG PET for detection of head and neck carcinomas with an unknown primary tumor. Ann Otolaryngol Chir Cervicofac. 2006;123:17–25. doi: 10.1016/S0003-438X(06)76634-8.
    1. Zanation AM, Sutton DK, Couch ME, Weissler MC, Shockley WW, Shores CG. Use, accuracy, and implications for patient management of [18F]-2-fluorodeoxyglucose-positron emission/computerized tomography for head and neck tumors. Laryngoscope. 2005;115:1186–1190. doi: 10.1097/01.MLG.0000163763.89647.9F.
    1. Nanni C, Rubello D, Castellucci P, et al. Role of 18F-FDG PET-CT imaging for the detection of an unknown primary tumor: preliminary results in 21 patients. Eur J Nucl Med Mol Imaging. 2005;32:589–592. doi: 10.1007/s00259-004-1734-3.
    1. Freudenberg LS, Fischer M, Antoch G, et al. Dual modality of 18F-fluorodeoxyglucose-positron emission tomography/computed tomography in patients with cervical carcinoma of unknown primary. Med Princ Pract. 2005;14:155–160. doi: 10.1159/000084632.
    1. Syed R, Bomanji JB, Nagabhushan N, et al. Impact of combined (18)F-FDG PET/CT in head and neck tumors. Br J Cancer. 2005;92:1046–1050. doi: 10.1038/sj.bjc.6602464.
    1. Gutzeit A, Antoch G, Kühl H, et al. Unknown primary tumors: detection with dual-modality PET/CT – initial experience. Radiology. 2005;234:227–234. doi: 10.1148/radiol.2341031554.
    1. Rödel R, Straehler-Pohl HJ, Palmedo H, et al. PET/CT imaging in head and neck tumors. Radiologe. 2004;44:1055–1059. doi: 10.1007/s00117-004-1125-6.
    1. Blaszyk H, Hartmann A, Bjornsson J. Cancer of unknown primary origin: a decade of experience in a community-based hospital. Am J Surg. 2007;194:833–837. doi: 10.1016/j.amjsurg.2007.08.039.
    1. Al-Brahim N, Ross C, Carter B, Chorneyko K. The value of postmortem examination in cases of metastasis of unknown origin-20-year retrospective data from a tertiary care center. Ann Diagn Pathol. 2005;9:77–80. doi: 10.1016/j.anndiagpath.2004.12.003.
    1. Mayordomo JI, Guerra JM, Guijarro C, et al. Neoplasms of unknown primary site: a clinicopathological study of autopsied patients. tumori. 1993;79:321–324.
    1. Le Chevalier T, Cvitkovic E, Caille P, et al. Early metastatic cancer of unknown primary origin at presentation. A clinical study of 302 consecutive autopsied patients. Arch Intern Med. 1988;148:2035–2039. doi: 10.1001/archinte.148.9.2035.
    1. Werner JA, Dünne AA, Myers JN. Functional anatomy of the lymphatic drainage system of the upper aerodigestive tract and its role in metastasis of squamous cell carcinoma. Head Neck. 2003;25:322–332. doi: 10.1002/hed.10257.
    1. Mawlawi O, Pan T, Macapinlac HA. PET/CT imaging techniques, considerations, and artifacts. J Thorac Imaging. 2006;21:99–110. doi: 10.1097/00005382-200605000-00002.
    1. Truong MT, Pan T, Erasmus JJ. Pitfalls in integrated CT-PET of the thorax: implications in oncologic imaging. J Thorac Imaging. 2006;21:111–122. doi: 10.1097/00005382-200605000-00003.
    1. Blodgett TM, Fukui MB, Snyderman CH, et al. Combined PET-CT in the head and neck: part 1. Physiologic, altered physiologic, and artifactual FDG uptake. Radiographics. 2005;25:897–912. doi: 10.1148/rg.254035156.
    1. Lim HS, Yoon W, Chung TW, et al. FDG PET/CT for the detection and evaluation of breast diseases: usefulness and limitations. Radiographics. 2007;27(suppl 1):S197–S213. doi: 10.1148/rg.27si075507.
    1. Fischbach F, Knollmann F, Griesshaber V, Freund T, Akkol E, Felix R. Detection of pulmonary nodules by multislice computed tomography: improved detection rate with reduced slice thickness. Eur Radiol. 2003;13:2378–2383. doi: 10.1007/s00330-003-1915-7.
    1. Ay MR, Zaidi H. Assessment of errors caused by X-ray scatter and use of contrast medium when using CT-based attenuation correction in PET. Eur J Nucl Med Mol Imaging. 2006;33:1301–1313. doi: 10.1007/s00259-006-0086-6.
    1. Antoch G, Freudenberg LS, Egelhof T, et al. Focal tracer uptake: a potential artifact in contrast-enhanced dual-modality PET/CT scans. J Nucl Med. 2002;43:1339–1342.
    1. Lauenstein TC, Semelka RC. Emerging techniques: whole-body screening and staging with MRI. J Magn Reson Imaging. 2006;24:489–498. doi: 10.1002/jmri.20666.
    1. Runge VM. Safety of magnetic resonance contrast media. Top Magn Reson Imaging. 2001;12:309–314. doi: 10.1097/00002142-200108000-00007.
    1. Plathow C, Walz M, Lichy MP, et al. Cost considerations for whole-body MRI and PET/CT as part of oncologic staging. Radiologe. 2008;48:384–396. doi: 10.1007/s00117-007-1547-z.
    1. Eustace S, Tello R, DeCarvalho V, Carey J, Melhem E, Yucel EK. Whole body turbo STIR MRI in unknown primary tumor detection. J Magn Reson Imaging. 1998;8:751–753. doi: 10.1002/jmri.1880080336.
    1. Brauck K, Zenge MO, Vogt FM, et al. Feasibility of whole-body MR with T2- and T1-weighted real-time steady-state free precession sequences during continuous table movement to depict metastases. Radiology. 2008;246:910–916. doi: 10.1148/radiol.2463062017.
    1. Kwee TC, Takahara T, Ochiai R, Nievelstein RAJ, Luijten PR. Diffusion-weighted whole-body imaging with background body signal suppression (DWIBS): features and potential applications in oncology. Eur Radiol. 2008;18:1937–1952. doi: 10.1007/s00330-008-0968-z.
    1. Schapira DV, Jarrett AR. The need to consider survival, outcome, and expense when evaluating and treating patients with unknown primary carcinoma. Arch Intern Med. 1995;155:2050–2054. doi: 10.1001/archinte.155.19.2050.
    1. Raber MN, Faintuch J, Abbruzzese JL, Sumrall C, Frost P. Continuous infusion 5-fluorouracil, etoposide and cis-diamminedichloroplatinum in patients with metastatic carcinoma of unknown primary origin. Ann Oncol. 1991;2:519–520.
    1. Haas I, Hoffmann TK, Engers R, Ganzer U. Diagnostic strategies in cervical carcinoma of an unknown primary (CUP) Eur Arch Otorhinolaryngol. 2002;259:325–333. doi: 10.1007/s004050100408.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren